Loading...

AKBA AKEBIA THERAPEUTICS INC Expansion Plans 8-K Filing

KB T

KB

AKEBIA THERAPEUTICS INC

(AKBA)

2026 8-K

Financial Results Announced

Lease Agreement Signed

Corporate Updates

Asset Acquisition

License Agreement Update

Financial Results Report

FDA Trial Update

Financial Statements

Management Changes

Financial Statements

Financial Results

Investor Presentation

Supply Agreement

Supply Agreement Update

Financial Results Announcement

Termination of License Agre...

Appointment of Erik Ostrows...

Annual Meeting of Stockholders

Financial Results Announcement

Supply Agreement Extension

Departure of Directors or C...

Earnings Report

Management Changes

Term Loan Facility

Appointment of Chief Accoun...

Results of Operations and F...

Supply Agreement Extension

Settlement Agreement

Earnings Report

Loan Agreement Amendment

Regulation FD Disclosure

Departure of Directors or C...

Delisting Notice

Regulation FD Disclosure

Workforce Reduction and Man...

Pre-Market Approval

Management Changes

Annual Meeting and Election...

Presentation at Jefferies H...

Settlement and License Agre...

Lease Assignment

FDA Response to Complete Re...

License Agreement with MEDI...

Compliance Notice from Nasdaq

Earnings Report

Special Meeting of Stockhol...

Bylaws Amendment

Approval for Vafseo in Europe

Adjournment of Special Meeting

Financial Results Announcement

Agreement Amendment

External Links:

On January 12, 2026, Akebia Therapeutics, Inc. announced key updates regarding its Vafseo® commercial business and provided revenue outlooks for Q4 2025, indicating a focus on its rare kidney disease pipeline's development. This filing is significant for investors as it relates to anticipated growth strategies.

AI Assistant

AKEBIA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.